About: Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics
Creator	Anderson, Evan Org, Krilov, Leonard Krilov@nyulangone, Leonard
Source	PMC
abstract	Palivizumab is the only licensed and effective immunoprophylaxis (IP) available to prevent respiratory syncytial virus (RSV) infection in high-risk infants including infants born at ≤35 weeks’ gestational age (wGA). In 2014, the American Academy of Pediatrics stopped recommending IP for otherwise healthy 29–34 wGA infants, stating that their risk of RSV hospitalization (RSVH) was similar to term infants. Recent studies have demonstrated a significant decline in IP use after 2014 that was accompanied by an increased risk of RSVH in 29–34 wGA infants vs term infants. Severity and healthcare utilization of RSVH were high among 29–34 wGA infants. In 2018, the National Perinatal Association developed guidelines advocating IP use in all ≤32 wGA infants and 32–35 wGA infants with additional risk factors. Risk factor predictive models can identify infants who are at risk for RSVH and promote cost-effective use of palivizumab until new methods of RSV prevention become available.
has issue date	2020-06-04(xsd:dateTime)
bibo:doi	10.1038/s41372-020-0689-y
has license	cc-by
sha1sum (hex)	b311221252d5c58736f612069429ad3832e2e1ff
schema:url	https://doi.org/10.1038/s41372-020-0689-y
resource representing a document's title	Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics
has PubMed Central identifier	PMC7271636
schema:publication	J Perinatol
resource representing a document's body	covid:b311221252d5c58736f612069429ad3832e2e1ff#body_text
is schema:about of	named entity 'decline' named entity 'infants' named entity 'term' named entity 'RSV' covid:arg/b311221252d5c58736f612069429ad3832e2e1ff named entity 'wGA' named entity 'infants' named entity 'American Academy' named entity 'infants' named entity 'studies' named entity 'high' named entity 'predictive models' named entity 'risk factors' named entity 'cost-effective' named entity 'Palivizumab' named entity 'RSV' named entity 'ICU' named entity 'chronic lung disease' named entity 'motavizumab' named entity 'wheezing' named entity 'Palivizumab' named entity 'RSV' named entity 'high-risk' named entity 'AbbVie' named entity 'RSV' named entity 'AAP' named entity 'outpatient' named entity 'preterm infants' named entity 'preterm infants' named entity 'born prematurely' named entity 'North Dakota' named entity 'palivizumab' named entity 'RSV' named entity 'IMV' named entity 'RSV' named entity 'risk factors' named entity 'immunoglobulin' named entity 'United States' named entity 'CHD' named entity 'risk factors' named entity 'preterm infants' named entity 'vaccine' named entity 'palivizumab' named entity 'prematurity' named entity 'lower respiratory tract infection' named entity 'community-acquired' named entity 'smoking during pregnancy' named entity 'comorbidities' named entity 'Palivizumab' named entity 'palivizumab' named entity 'Pfizer' named entity 'preterm infants' named entity 'ICU' named entity 'RSV' named entity '0.01' named entity 'preterm infants' named entity 'Pfizer' named entity '95% CI' named entity 'RSV' named entity 'respiratory syncytial virus' named entity 'high-risk' named entity 'palivizumab' named entity 'LRTI' named entity 'preterm infants' named entity 'RSV' named entity 'Creative Commons license' named entity 'confirmatory diagnosis' named entity 'LRTI' named entity 'RSV' named entity 'RSV' named entity 'American Academy of Pediatrics' named entity 'RSV' named entity 'IMV' named entity 'palivizumab' named entity 'bronchiolitis' named entity 'Pfizer' named entity 'preterm infants' named entity 'controlled trials' named entity 'Creative Commons Attribution 4.0' named entity 'RSV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software